Domov › Folikulárny lymfóm › New York › New York City
Klinické štúdie Folikulárny lymfóm v meste New York City, NY
24 štúdií pre Folikulárny lymfóm hľadá účastníkov v zariadeniach v meste New York City a okolí (do cca 30 míľ). Otvorte štúdiu a zistite, kto sa môže zapojiť a ako kontaktovať tím.
Oficiálny text štúdie (anglicky)
Hľadáte účastníkov do štúdie? Zvýraznite ju na začiatku tejto stránky – $99 na 30 dní →
A Dose-Escalation and Expansion Study of Tacabrutideg (BGB-16673) in Participants With B-Cell Malignancies
Prebieha náborFáza 1/2
- Columbia University Medical Center, New York
- Weill Cornell Medical College Newyork Presbyterian Hospital, New York
- Memorial Sloan Kettering Cancer Center Mskcc, New York
Testing Addition of an Anti-cancer Drug, Vorasidenib to Temozolomide, After Radiation for Advanced Brain Cancer
Prebieha náborFáza 3
- Laura and Isaac Perlmutter Cancer Center at NYU Langone, New York
- NYP/Columbia University Medical Center/Herbert Irving Comprehensive Cancer Center, New York
- Memorial Sloan Kettering Cancer Center, New York
A Study to Evaluate Safety, PK, PD and Efficacy of AZD5492, a T Cell-engaging Antibody Targeting CD20 in Subjects With R/R B-Cell Malignancies.
Prebieha náborFáza 1/2
- Research Site, New York
- Research Site, New York
Epco, Zanu, Ritux for R/R FL or MZL
Prebieha náborFáza 2
- Memorial Sloan Kettering Cancer Center, New York
A Study of LY4152199 in Participants With Previously Treated B-cell Malignancies (BAF_FRontier-1 )
Prebieha náborFáza 1
- New York University (NYU) Clinical Cancer Center, New York
- Weill Cornell Medicine, New York
- David H. Koch Center for Cancer Care at Memorial Sloan Kettering Cancer Center, New York
A Study of Debio 0123 in Combination With Temozolomide in Adult Participants With Recurrent or Progressive Glioblastoma and of Debio 0123 in Combination With Temozolomide and Radiotherapy in Adult Participants With Newly Diagnosed Glioblastoma
Prebieha náborFáza 1/2
- New York University Langone Medical Center, New York
- David H. Koch Center for Cancer Care at Memorial Sloan Kettering Cancer Center, New York
A Study of LY4584180 in Adult Participants With Previously Treated Blood Cancers
Prebieha náborFáza 1
- Columbia University, New York
A Study of Surovatamig (AZD0486) Plus Rituximab in Previously Untreated Follicular Lymphoma Patients
Prebieha náborFáza 3
- Research Site, New York
- Research Site, New York
- Research Site, New York
Surovatamig (AZD0486) as Monotherapy in Participants With Relapsed/Refractory (R/R) B-cell NHL
Prebieha náborFáza 2
- Research Site, New York
Study to Evaluate the Efficacy and Safety of [177Lu]Lu-DOTA-TATE in Patients With Grade 1 and Grade 2 Advanced GEP-NET
Prebieha náborFáza 3
- Mount Sinai Medical Center, New York
A Trial to Learn if Odronextamab is Safe and Well-Tolerated and How Well it Works Compared to Rituximab Combined With Different Types of Chemotherapy for Adult Participants With Previously Untreated Follicular Lymphoma
Prebieha náborFáza 3
- Icahn School of Medicine at Mt Sinai, New York
Testing the Addition of an Anti-Cancer Drug, Triapine, to the Usual Radiation Therapy for Recurrent Glioblastoma or Astrocytoma
Prebieha náborFáza 1
- Laura and Isaac Perlmutter Cancer Center at NYU Langone, New York
- NYP/Columbia University Medical Center/Herbert Irving Comprehensive Cancer Center, New York
SIGMA (Safusidenib in IDH1 Mutant Glioma Maintenance)
Prebieha náborFáza 3
- NYU Langone Health, New York
- Icahn School of Medicine at Mount Sinai, New York
- Columbia University Medical Center, New York
- a 1 ďalších
A Study of ARC-02 in B-cell NHL
Prebieha náborFáza 1
- NYU Langone, New York
Study of Rondecabtagene Autoleucel in Aggressive Large B-Cell Lymphoma
Prebieha náborFáza 1/2
- David H. Koch Center for Cancer Care at Memorial Sloan Kettering Cancer Center, New York
rTMS and Cognitive-behavioral Therapy for Cocaine Use Disorder
Prebieha nábor
- New York State Psychiatric Institute (NYSPI) / Substance Treatment and Research Service (STARS), New York
A Study of Mosunetuzumab Alone or With Zanubrutinib in People With Follicular Lymphoma
Prebieha náborFáza 2
- Memorial Sloan Kettering Cancer Center, New York
This is a Phase 1 Study to Evaluate the Safety of LTZ-301 in Patients With Non-Hodgkin Lymphoma
Prebieha náborFáza 1
- Memorial Sloan Kettering Cancer Center - Bergen, New York
Chronic CED of TPT for Recurrent Malignant Glioma
Prebieha náborFáza 1
- Columbia University Irving Medical Center / NewYork-Presbyterian Hospital, New York
Epcoritamab and Rituximab for First-line Follicular Lymphoma
Prebieha náborFáza 2
- Icahn School of Medicine at Mount Sinai Hospital, New York
Epcoritamab in Patients With Follicular Lymphoma Not Accomplishing a CR With Upfront Chemoimmunotherapy
Prebieha náborFáza 2
- Icahn School of Medicine at Mount Sinai, New York
A Study of Reduced Dose Radiation Therapy for People With B-Cell Lymphomas
Prebieha náborFáza 3
- Memorial Sloan Kettering Cancer Center (All Protocol Activities), New York
Study of SGR-1505 in Mature B-Cell Neoplasms
Prebieha náborFáza 1
- Weill Cornell, New York
SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
Prebieha náborObservačná štúdia
- Massive Bio SYNERGY-AI site, New York
Štúdie Folikulárny lymfóm v iných mestách
- Milwaukee, WI19 štúdií
- Nashville, TN18 štúdií
- Houston, TX18 štúdií
- Boston, MA17 štúdií
- Baldwin Park, CA16 štúdií
- Seattle, WA15 štúdií
- Durham, NC15 štúdií
- Salt Lake City, UT13 štúdií
- Columbus, OH13 štúdií
- Chicago, IL12 štúdií
- San Antonio, TX12 štúdií
- Philadelphia, PA12 štúdií
Iné štúdie v New York City
- Rakovina prsníka136 štúdií
- Nemalobunkový karcinóm pľúc121 štúdií
- Rakovina (všetky typy)109 štúdií
- Rakovina prostaty103 štúdií
- Metastatická rakovina93 štúdií
- Kolorektálny karcinóm78 štúdií
- Rakovina vaječníkov69 štúdií
- Rakovina pľúc60 štúdií
- Mnohonásobný myelóm60 štúdií
- Rakovina pankreasu60 štúdií
- Rakovina endometria52 štúdií
- Akútna myeloidná leukémia51 štúdií
Z ClinicalTrials.gov, dáta načítané 6. 10. 2026. Každá štúdia má vlastné kritériá oprávnenosti; tím štúdie rozhoduje o účasti.